Mastrapasqua Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Mastrapasqua Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$2.69M	Sell	7,743 -150	-2%	-$52.5K	0.32%	65
2023 Q2	$2.78M	Sell	7,893 -28	-0.4%	-$9.43K	0.31%	65
2023 Q1	$2.5M	Buy	7,921 +348	+5%	+$104K	0.31%	68
2022 Q4	$2.19M	Buy	7,573 +776	+11%	+$237K	0.29%	77
2022 Q3	$1.97M	Buy	6,797 +1,335	+24%	+$384K	0.28%	78
2022 Q2	$1.54M	Buy	5,462 +376	+7%	+$101K	0.21%	92
2022 Q1	$1.33M	Buy	+5,086	New	+$1.21M	0.15%	108
2021 Q4	–	Sell	-10,184	Closed	-$1.85M	–	147
2021 Q3	$1.85M	Sell	10,184 -48	-0.5%	-$9.37K	0.2%	94
2021 Q2	$2.06M	Buy	10,232 +91	+0.9%	+$19K	0.22%	86
2021 Q1	$2.18M	Buy	10,141 +755	+8%	+$166K	0.25%	84
2020 Q4	$2.22M	Sell	9,386 -46	-0.5%	-$10.6K	0.29%	75
2020 Q3	$2.57M	Sell	9,432 -89	-0.9%	-$24.6K	0.36%	70
2020 Q2	$2.76M	Buy	9,521 +660	+7%	+$179K	0.43%	64
2020 Q1	$2.11M	Buy	8,861 +821	+10%	+$188K	0.41%	63
2019 Q4	$1.76M	Buy	+8,040	New	+$1.63M	0.29%	79

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mastrapasqua Asset Management's VRTX Position: Q3 2023 in Review

Mastrapasqua Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 1.9% in Q3 2023, selling an estimated $52.5K and leaving 7,743 shares worth $2.69M. The position accounts for 0.32% of the portfolio, ranked #65.

Mastrapasqua Asset Management first reported a position in VRTX in Q4 2019 and has held it in 15 quarters since. The position peaked at $2.78M in Q2 2023. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Mastrapasqua Asset Management held 7,743 shares of Vertex Pharmaceuticals worth $2.69M as of Q3 2023.
Mastrapasqua Asset Management sold 150 Vertex Pharmaceuticals shares in Q3 2023, an estimated $52.5K.
Vertex Pharmaceuticals made up 0.32% of Mastrapasqua Asset Management's portfolio in Q3 2023, its #65 holding.
Mastrapasqua Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 15 quarters since.
Mastrapasqua Asset Management's Vertex Pharmaceuticals position peaked at $2.78M in Q2 2023.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Mastrapasqua Asset Management's 13F filing for Q3 2023, filed 25 Oct 2023.